The FDA decision on Arcutis Biotherapeutics Inc.’s (ARQT) ZORYVE cream 0.05% for the expanded use in treating atopic dermatitis in children aged 2 to 5 years is anticipated on October 13, 2025. Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States. The disease appears as a red, intensely itchy rash that can occur anywhere on the body and may present differently in children and adults.ZORYVE cream, a once-daily selective phosphodiesterase-4 (PDE4) inhibitor, is approved in the U.S. at 0.3% strength for treating plaque psoriasis in adult and pediatric patients aged 6 and older, and at 0.15% strength for atopic dermatitis in adult and pediatric patients 6 years of age and older. ARQT closed Friday’s (September 26, 2025) trading at $17.57, up $5.02.